Browse News
Filter News
Found 804,965 articles
-
Following in the footsteps of Bristol Myers Squibb and Eli Lilly, AstraZeneca on Tuesday jumped into the radiopharmaceuticals space by acquiring Fusion Pharmaceuticals in a deal worth $2.4 billion.
-
Orchard Therapeutics on Monday secured the FDA’s first approval for an autologous gene therapy to treat the rare metabolic disease metachromatic leukodystrophy in children.
-
To help support the launch of Lyfgenia, bluebird bio on Monday entered into a five-year term loan deal with Hercules Capital that will extend the biotech’s cash runway through the first quarter of 2026.
-
An appellate court sided with Regeneron versus Novartis on Monday, agreeing that anti-VEGF pre-filled syringes constitute a distinct market than those sold in vials. The case involves Regeneron’s Eylea and Novartis’ Lucentis eye treatments.
-
BioSpace's 2024 Salary Report explores the average salaries and salary trends of life sciences professionals.
-
Follow along as BioSpace keeps you up to date on the latest pharma and biotech M&As, from announcements to closings.
-
Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
3/19/2024
Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, announced the launch of Versavo® in the United Kingdom.
-
Brain Recordings in People Before Surgery Reveal How All Minds Plan What to Say Prior to Speaking
3/19/2024
A new study in people undergoing surgery to treat seizures related to epilepsy shows that pauses in speech reveal information about how people's brains plan and produce speech.
-
CB Scientific, Inc. Concludes its Annual Meeting of Stockholders
3/19/2024
CB Scientific, Inc., a designer, manufacturer and distributor of non-invasive ambulatory cardiac monitoring products and services, announced that the company successfully concluded its Annual Meeting of Stockholders on Thursday, March 14, 2024 as planned.
-
Health Canada Accepts for Review New Drug Submission for Tofersen for Treatment of Rare, Genetic Form of ALS
3/19/2024
Biogen Canada Inc. announced that Health Canada has accepted for review a New Drug Submission for tofersen for the treatment of amyotrophic lateral sclerosis in adults who have a mutation in the superoxide dismutase 1 gene.
-
Cytovale's Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application
3/19/2024
Cytovale® announced new data that demonstrates how its IntelliSep® test reduced cost of care and improved efficiency of sepsis care for a large U.S. academic center.
-
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
3/19/2024
CSL Vifor announced that Health Canada has authorized Ferinject for the intravenous treatment of iron deficiency anemia in adult and pediatric patients one year of age and older when oral iron preparations are not tolerated or are ineffective, as well as for the treatment of iron deficiency in adult patients with heart failure and New York Heart Association class II/III* to improve exercise capacity.
-
Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies
3/19/2024
Engrail Therapeutics today announced the close of an oversubscribed $157 million Series B financing round.
-
Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer
3/19/2024
Conduit Pharmaceuticals Inc. announced the appointment of Dr. Joanne Holland as Chief Scientific Officer.
-
Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024
3/19/2024
Tonix Pharmaceuticals Holding Corp. today announced that it will achieve its goal of transitioning to a fully integrated pharmaceutical company on April 1, 2024.
-
Morphic Appoints Dr. Simon Cooper as Chief Medical Officer
3/19/2024
Morphic Therapeutic today announced that Simon Cooper, M.B.B.S., has joined the Company as Chief Medical Officer.
-
Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
3/19/2024
Revive Therapeutics Ltd. announced that the FDA advised the Company to submit a Type C meeting request to discuss evaluating a proposed Phase 2 clinical study of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long COVID.
-
Cytek® Biosciences Names William McCombe Chief Financial Officer
3/19/2024
Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that William (Bill) McCombe has been appointed chief financial officer of the company effective immediately.
-
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
3/19/2024
Tourmaline Bio, Inc. announced its financial results for the fourth quarter and year ended December 31, 2023 and outlined recent business highlights.
-
Bionano Announces Publication of a Breast Cancer Study Showing that the Number of SVs Detected with OGM May Be Related to Prognosis, Tumor Progression and Chemotherapy Resistance
3/19/2024
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study of optical genome mapping (OGM) in hereditary breast and ovarian cancer (HBOC) syndrome showing that when tumors exhibited higher overall numbers of structural variations (SVs) they tended to have more mutated genes and altered signaling pathways, which may correlate with poor prognosis, tumor progression and chemotherapy resistance.